These are links to recent news stories that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Ocrelizumab effective in all types of MS
Ocrelizumab reduced the risk of progression in primary progressive MS by a quarter compared to placebo - the first drug to show an effect on progressive MS. It also caused increased walking speed, fewer new lesions and slower brain atrophy. Other studies in relapsing MS found ocrelizumab reduced relapses by almost half compared to beta interferon. Reported at ECTRIMS
MS Trust link: Ocrelizumab
Daclizumab study results
New data showed that daclizumab reduced relapses by 45% compared to beta interferon and almost twice as many people in daclizumab group had no relapse, no progression and no new lesions after two years. The measure of disability progression showed the drugs had a similar effect. People in the daclizumab group had more side effects. Reported at ECTRIMS
MS Trust link: Daclizumab (Zinbryta)
Gilenya (fingolimod) long-term benefits
Seven year follow up data from the FREEDOMS and FREEDOMS II trials shows 31.2% to 44.8% of people continues to have NEDA (no relapses, MRI lesions, brain atrophy and disability progression) in each of the years three to seven. Including brain atrophy in measures at year one increased the ability to predict outcomes at year seven. Reported at ECTRIMS
Source: Novartis press release
MS Trust link: Gilenya (fingolimod)
Aubagio (teriflunomide) real world study
An ongoing real world study of teriflunomide found that after two years on the drug, treatment satisfaction scores had improved by almost a quarter and scores on the Multiple Sclerosis Performance Scale had gone up fractionally. Seven in tem people reported an adverse effect. Reported at ECTRIMS
Source: MD Magazine
MS Trust link: Aubagio (teriflunomide)
Sativex in clinical practice
An observational study found that people taking Sativex showed similar results to those seen in the formal trials. After three months about a quarter showed at least 30% improvement in spasticity measures, though almost a quarter had stopped treatment - mostly due to lack of efficacy or side effects. At three months, average dose was 5.1 sprays. Reported at ECTRIMS
Source: MedPage Today
MS Trust link: Sativex